Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 6/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703953 | 1.00 | NR1H2 (0.40) | NR1H2CNR2RIPK1MEN1KMT2A | |
| SCHEMBL17001728 | 1.00 | NR1H2 (0.40) | NR1H2CNR2RIPK1MEN1KMT2A | |
| SCHEMBL12424302 | 0.89 | NR1H2 (0.35) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19127641 | 0.88 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL21730405 | 0.88 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19540623 | 0.88 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL26922100 | 0.88 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL17924712 | 0.86 | NR1H2 (0.34) | NR1H2MEN1KMT2AHDAC8CHRM2 | |
| SCHEMBL16551797 | 0.86 | NR1H2 (0.34) | NR1H2MEN1KMT2AHDAC8CHRM2 | |
| SCHEMBL16749349 | 0.86 | NR1H2 (0.34) | NR1H2MEN1KMT2AHDAC8CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | AARHUS UNIVERSITET (DK) | 2025-09-16 | — | — | US | disclosed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4565584-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-06-11 | — | — | EP | disclosed |
| CN-115867282-B | 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use | 奈克斯拉制药英国有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2011053705-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | NR1H2 1128/4885CNR2 4297/4885RIPK1 3153/4885 |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | NR1H2 39/4885CNR2 52/4885RIPK1 2341/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | NR1H2 2552/4885CNR2 3255/4885RIPK1 2996/4885 |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | NR1H2 138/4885CNR2 3302/4885RIPK1 2335/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | NR1H2 1312/4885CNR2 297/4885RIPK1 2710/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | NR1H2 550/4885CNR2 155/4885RIPK1 2681/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | NR1H2 3296/4885CNR2 390/4885RIPK1 2050/4885 |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NR1H2 160/4885CNR2 79/4885RIPK1 2241/4885 |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | DLD, HIF1A, DPYD | NR1H2 3171/4885CNR2 818/4885RIPK1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.